SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

HCPLive 5 Stories in Under 5: Week of 01/04

HCPLive 5 Stories in Under 5: Week of 01/04

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Latest News

HCPLive 5 Stories in Under 5: Week of 01/11

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

HCPLive 5 Stories in Under 5: Week of 01/04

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

News All Time

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Gestational Diabetes Linked to Reduced Lung Function in Children

Gestational Diabetes Linked to Reduced Lung Function in Children

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

5 Endocrinology Headlines You Missed in November 2025

5 Endocrinology Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management

Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management

Evidence builds for disrupted mitochondria as cause of Parkinson's

For decades, scientists have known that mitochondria, which produce energy inside our cells, malfunction in Parkinson's disease. But a critical question remained: do the failing mitochondria cause Parkinson's, or do they ...

Keto diet associated with reduced depressive symptoms, anxiety results remain mixed

Researchers led by St Michael's Hospital in Toronto report that ketogenic diets are associated with modest reductions in depressive symptoms in adults, while evidence for anxiety remains uncertain.

Some women start menopause after surgery or medical treatment: Here's how it's different

For most women, menopause occurs naturally around the age of 49. In the lead up to menopause, the quality and quantity of eggs declines over time. Then the ovaries stop releasing eggs completely.

How painkillers can contribute to anemia in cancer patients

Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the iron metabolism of liver cancer cells and can thus contribute to iron deficiency and anemia in cancer ...

Study reveals how uterine contractions are regulated by stretch and pressure during childbirth

When labor begins, the uterus must coordinate rhythmic, well-timed contractions to deliver the baby safely. While hormones such as progesterone and oxytocin are key contributors to that process, scientists have long suspected ...

Recommended News For You

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

How AI will transform mental health support for patients with breast cancer

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.

In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

"We Caught It Early": Advantage or Disadvantage?

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

Recommended Articles For You

Overcoming Immunotherapy Resistance: Novel Checkpoints, Biomarkers, and Emerging Therapeutic Strategies 

The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v 

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy 

Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

2.

Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.

3.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

4.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

5.

A protein with new anticancer activity has been identified

1.

Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer

2.

Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology

3.

Exploring The Causes and Consequences of Low Transferrin Saturation

4.

Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post

5.

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

3.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot